ClinicalTrials.gg
Not yet recruitingNCT07604727APAF-CSPUpdated May 22, 2026

AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation

An interventional study of Conduction System Pacing and Cardiac resynchronization therapy in Atrial Fibrillation (AF), Heart Failure and Cardiac Pacing, sponsored by University Medical Center Groningen. Not yet recruiting at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Atrial Fibrillation by University Medical Center Groningen — 3 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · University Medical Center Groningen.

Planned enrollment
6th of 13
292 · median 220
Started
2026
the only one that year
No phase
9 of 16
3 open now
Registered
16th of 16
by date

Among the 16 studies in Atrial Fibrillation by University Medical Center Groningen, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 16th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 16 studies in Atrial Fibrillation by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Atrial Fibrillation by University Medical Center Groningen, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if conduction system pacing works as well as cardiac resynchronization therapy (CRT) post atrioventricular (AV) node ablation in adult patients with symptomatic heart failure and atrial fibrillation that is not suitable for rhythm control.

The main question it aims to answer is:

Is AV node ablation with conduction system pacing noninferior to AV node ablation with CRT for the hierarchical composite outcome of all-cause mortality, heart failure hospitalization or urgent heart failure visit, and meaningful improvement in heart failure-related quality of life?

Participants will undergo:

  • An AV node ablation and be randomly assigned to receive either a conduction system pacing or a CRT.
  • Attend follow-up visits (in clinic or by telephone) at baseline, intervention day, 3-month, 12-month, 24-month, and 36-month after the procedure.
  • Complete questionnaires about heart failure symptoms and quality of life at baseline, 12 months, and yearly.
  • Have an echocardiogram, an electrocardiogram, and blood tests at baseline and 1 year
  • At selected centers: they will be asked to wear a bracelet that measures arterial stiffness for 30 minutes and provide a urine sample at baseline and 1 year.
Read the detailed description
  • Study Rationale:

Therapeutic options for patients with symptomatic HF and AF that is not suitable for rhythm control are limited to pharmacological rate control and/or AV node ablation plus CRT implantation (Class IIa, Level of Evidence B). CSP is gaining more and more attention, and it has the advantage of utilizing the native conduction system to activate both ventricles simultaneously. This would achieve more physiologically synchronized ventricular contraction and circulation dynamics. We hypothesize that conduction system pacing would be as efficient as CRT pacing in patients with symptomatic heart failure and AF that is not suitable for rhythm control who are receiving the "ablate and pace" treatment strategy.

+Objective:

  1. Primary Objective:

    To compare AV node ablation with conduction system pacing versus AV node ablation with cardiac resynchronization therapy (CRT) among the trial population with respect to the hierarchical composite endpoint of all-cause mortality, HF hospitalization or unplanned/urgent HF visit, and ≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

  2. Secondary Objectives:

    To determine the effect of AV node ablation with conduction system pacing compared to AV node ablation with cardiac resynchronization therapy (CRT) among the trial population in the following outcomes:

    -≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

    • Quality of life measures (EQ-5D and AFEQT questionnaires). -HF hospitalization or unplanned/urgent HF visit. -Cardiovascular related hospitalization. -All-cause mortality. -Cardiovascular related mortality. Tertiary (Exploratory) Objectives: To determine the effect of AV node ablation with conduction system pacing compared to AV node ablation with cardiac resynchronization therapy (CRT) among the trial population in the following outcomes:
    • Duration of hospitalization for cardiovascular causes
    • Worsening heart failure (NYHA class at baseline,1 year and at end of follow-up),
    • Healthcare costs and cost-effectiveness,
    • Trends of NT-proBNP levels at baseline and follow up
    • Change in left ventricular ejection fraction (LVEF) at baseline and 1 year
    • Change in renal function metrics (Glomerular Filtration Rate (GFR), Creatinine (Cr) and blood Urea levels (BUN)) at baseline and 1 year.
    • Change in urine Microalbumin (by urine dipstick) at baseline and 1 year (only in the subgroup analysis).
    • Change in measured arterial stiffness index measured by the photoplethysmography (PPG) signals through a non-invasive blood-volume sensing wearable bracelet, at baseline and 1 year (only in the subgroup analysis).
    • Short-term safety outcomes: This includes the composite of short-term (i.e. within 3 months) post procedure related complications (i.e. Cardiac tamponade, Pneumothorax, postoperative wound infection, Pocket hematomas, lead dislodgment, vascular injury, Thromboembolism, and Pericarditis).
    • Long term safety outcomes: This includes the composite of long-term (i.e. within 3 years) post procedure related complications (Device and Lead integrity related complications (i.e. lead dislodgment, lead malfunction, generator malfunction, lead related infections)).

      • Study design:

    The APAF-CSP trial is a prospective, multicenter, international, randomized, open-label, non-inferiority, parallel-arms trial. Patients who have atrial fibrillation (AF), that is not suitable for rhythm control, and a history of at least one hospitalization or unplanned/urgent care visit due to heart failure within the last 2 years, regardless of left ventricular ejection fraction or QRS duration, will be invited to participate. The trial will take place in 23 participating hospitals in Europe (Netherlands, Germany, Italy and France).

    +Study population: Adult patients aged 18 years or older, with confirmed AF that is unsuitable for rhythm control and symptomatic HF (with a history of at least one hospitalization or unplanned/urgent care visit due to HF exacerbation within the 2 years before enrolment), regardless of left ventricular ejection fraction or QRS duration, will be invited to participate in this trial. Based on sample size estimations, the trial needs 292 patients with a median follow-up of 2.5 years.

    +Intervention: All patients meeting the inclusion criteria and not meeting any exclusion criteria will be randomized in a 1:1 ratio to undergo either AV node ablation with CSP or AV node ablation with CRT implantation. Throughout the trial, patients will be followed up at predefined intervals for endpoint data collection.

    +Main study endpoint: The hierarchical primary composite endpoint is the composite of all-cause mortality, HF hospitalization or unplanned/urgent HF visit, and ≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ).

    +Nature and extent of the burden and risks associated with participation, benefit and group relatedness: AV node catheter ablation and pacemaker implantation, whether CRT or CSP, are well-established and safe techniques. They are well-known for their efficiency for rate control in the appropriate population. The follow-up assessments will be conducted either physically (i.e. patient visits) and/or (when possible) remotely (i.e. telephone encounter) to minimize patient effort. Additional study procedures, such as transthoracic echocardiography and blood sample collection, will be performed at baseline during the screening assessment and during the 1-year follow-up visit. These procedures are part of usual clinical care for these patients undergoing AV nodal ablation with pacemaker implantation. Consequently, the additional effort and time to fill out a few "Quality-of-Life" questionnaires are determined to be the main extra burden that consumes time for both the patient and the treating physician. However, this increased burden is non-invasive and will be highlighted in the consent/participation form. In pre-selected centers (subgroup analyses), a urine sample for the microalbumin check will be collected at baseline and the 1-year visit. Furthermore, the vascular stiffness index (VSI) will be measured by a wearable bracelet. This VSI measurement will be performed at the baseline visit and at the 1-year follow up visit, where the participant will be asked to wear the device for 30 minutes (during the visit). The VSI recording and urine microalbumin check are painless, non-invasive and fully funded by the study. The patient will not be required to come for an extra visit to the study site for the sole reason of this recording or for the urine sample, and instead, this is incorporated into the scheduled study visits. However, the increased burden of providing a urine sample and wearing the bracelet during the visit is fully acknowledged and will be highlighted in the consent/participation forms.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Heart Failure
  • Cardiac Pacing

Keywords

  • Conduction System Pacing
  • Cardiac Resynchronization
  • Atrial Fibrillation
  • AV Nodal Ablation
  • Heart Failure
  • All-cause Mortality
  • Quality of Life
  • HF hospitalization
  • Unplanned/urgent HF visit
  • Arterial Stiffness Index
  • Photoplethysmography
  • APAF-CSP
  • EQ-5D
  • AFEQT
  • Kansas City Cardiomyopathy Questionnaire (KCCQ)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or above.
  • Patient is diagnosed with AF and deemed not amenable to rhythm control. This diagnosis of AF will be demonstrated by at least one Electrocardiograph () showing AF that was performed within one year prior to enrollment.
  • Has history of stable heart failure (regardless ) and has a history of at least one HF related hospitalization or emergency room/urgent care visit within 2 years prior to enrollment, despite being on maximally tolerable guideline directed medical therapy.
  • Willing and capable to provide .

Exclusion criteria

Exclusion Criteria:

  • functional class IV.
  • Severe concomitant non-cardiac disease.
  • Patient who require any cardiac surgical intervention.
  • Previously implanted pacing devices (pacemaker/ICD/CRT) with ≥40% pacing burden.
  • Any of the following within the 3 months prior to enrollment:

    • Myocardial infarction
    • Unstable angina
    • Percutaneous coronary intervention
    • Stroke or
    • Significant bleeding
    • Pericarditis/effusions
  • Coronary artery bypass surgery/atriotomy within 6 months prior to enrolment.
  • Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
292 participants (estimated)

Study arms

  • Other
    CSP Group (Intervention Group)

    AV node ablation plus Conduction System Pacing implantation. CSP is established pacing strategy evaluated in comparison with CRT.

    Procedure: Conduction System Pacing

  • Active comparator
    CRT Group (Control Group)

    AV node ablation plus cardiac resynchronization therapy implantation. CRT is established standard pacing strategy.

    Procedure: Cardiac resynchronization therapy

Interventions

  • ProcedureConduction System Pacing

    The implantation of a pacing device with a pacing lead that aims to capture and pace the native conduction system.

  • ProcedureCardiac resynchronization therapy

    The implantation of a pacing device with a pacing leads that aims to capture and pace both ventricles in a synchronized fashion, to achieve the best possible hemodynamic parameters and synchrony.

06

What researchers measure

Primary outcomes

  1. The hierarchical composite endpoint of all-cause mortality, HF hospitalization or unplanned/urgent HF visit, and ≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) scores are scaled 0-100 (the higher score indicates a better condition).

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

Secondary outcomes

  1. Major secondary endpoint: ≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) scores are scaled 0-100 (the higher score indicates a better condition).

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

  2. Quality of Life Improvement (AFEQT Questionnaire)

    The AFEQT is a disease-specific questionnaire that focuses on assessing the impact of AF on a person's QoL. It covers several domains, including symptoms, daily activities, treatment concerns, and treatment satisfaction. The AFEQT provides scores for each domain as well as a total score, allowing for a comprehensive evaluation of the specific aspects affected by AF on an individual's QoL. Scale 0-100, higher scores indicate no limitation or disability.

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

  3. Quality of Life Improvement (EQ-5D-5L Questionnaire)

    The EQ-5D-5L is a questionnaire used to assess health-related QoL across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels indicating the level of problems experienced by the individual ( 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems). The EQ-5D-5L also generates a summary index score that represents overall health status based on societal preferences for different health states.

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

  4. HF Hospitalization or Unplanned/urgent HF Visit

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

  5. Cardiovascular Related Hospitalization

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

  6. All-cause Mortality

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

  7. Cardiovascular Related Mortality

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

Other outcomes

  1. Duration of hospitalization for cardiovascular causes

    Tertiary (Exploratory) Endpoint

    Time frame: From enrollment to the end of follow up (median follow-up of 2.5 years)

  2. Clinical heart failure status (New York Heart Association (NYHA) Functional Classification)

    Tertiary (Exploratory) Endpoint. NYHA Classification (scale I-IV): Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.

    Time frame: At baseline,1-year, and at end of follow-up (median of 2.5 years follow-up).

  3. Healthcare costs and cost-effectiveness parameters

    Tertiary (Exploratory) Endpoint

    Time frame: At the end of follow up (Median of 2.5 years follow up)

  4. NT-proBNP levels

    Tertiary (Exploratory) Endpoint

    Time frame: At baseline and 1-year follow up.

  5. Left ventricular ejection fraction (LVEF)

    Tertiary (Exploratory) Endpoint

    Time frame: At baseline and 1-year follow up.

  6. Glomerular Filtration Rate (GFR)

    Tertiary (Exploratory) Endpoint

    Time frame: At baseline and 1-year follow up.

  7. Creatinine (Cr) level

    Tertiary (Exploratory) Endpoint

    Time frame: At baseline and 1-year follow up.

  8. Blood Urea level (BUN)

    Tertiary (Exploratory) Endpoint

    Time frame: At baseline and 1-year follow up.

  9. Urine Microalbumin levels (Only in the subgroup analysis in selected centers)

    Tertiary (Exploratory) Endpoint

    Time frame: At baseline and 1-year follow up.

  10. Arterial stiffness index measured by the photoplethysmography (PPG) signals (Only in the subgroup analysis in selected centers).

    Tertiary (Exploratory) Endpoint

    Time frame: At baseline and 1-year follow up.

  11. Short-term safety endpoints

    Tertiary (Exploratory) Endpoints. These includes the short-term (i.e. within 3 months) post procedure related complications (i.e. Cardiac tamponade, Pneumothorax, postoperative wound infection, Pocket hematomas, lead dislodgment, vascular injury, Thromboembolism, and Pericarditis)

    Time frame: Within 3 months post the procedure

  12. Long term safety endpoints

    Tertiary (Exploratory) Endpoints. These includes the long-term (i.e. within 3 years) post procedure related complications (Device and Lead integrity related complications (i.e. lead dislodgment, lead malfunction, generator malfunction, lead related infections)).

    Time frame: Within 3 years post the procedure

07

Study locations

23 sites
08

References and documents

Publications

  • Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):15-25. doi: 10.1161/CIRCEP.110.958033. Epub 2010 Dec 15. PubMed 21160035 ↗
  • Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390. doi: 10.1016/j.jacc.2020.09.542. PubMed 33183512 ↗
  • Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013 Jan;36(1):122-33. doi: 10.1111/j.1540-8159.2012.03513.x. Epub 2012 Sep 14. PubMed 22978656 ↗
  • Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis. Circulation. 2000 Mar 14;101(10):1138-44. doi: 10.1161/01.cir.101.10.1138. PubMed 10715260 ↗
  • Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol. 2003 May 21;41(10):1697-702. doi: 10.1016/s0735-1097(03)00338-3. PubMed 12767649 ↗
  • Ueng KC, Tsai TP, Tsai CF, Wu DJ, Lin CS, Lee SH, Chen SA. Acute and long-term effects of atrioventricular junction ablation and VVIR pacemaker in symptomatic patients with chronic lone atrial fibrillation and normal ventricular response. J Cardiovasc Electrophysiol. 2001 Mar;12(3):303-9. doi: 10.1046/j.1540-8167.2001.00303.x. PubMed 11291803 ↗
  • Brignole M, Menozzi C, Gianfranchi L, Musso G, Mureddu R, Bottoni N, Lolli G. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation. 1998 Sep 8;98(10):953-60. doi: 10.1161/01.cir.98.10.953. PubMed 9737514 ↗
  • Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, Gasparini M, Raviele A, Lolli G, Paparella N, Acquarone S. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation. 1997 Oct 21;96(8):2617-24. doi: 10.1161/01.cir.96.8.2617. PubMed 9355902 ↗
  • Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, Oddone D, Gaggioli G. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol. 1994 Aug 1;74(3):242-6. doi: 10.1016/0002-9149(94)90364-6. PubMed 8037128 ↗
  • Yeung-Lai-Wah JA, Qi A, Uzun O, Humphries K, Kerr CR. Long-term survival following radiofrequency catheter ablation of atrioventricular junction for atrial fibrillation: clinical and ablation determinants of mortality. J Interv Card Electrophysiol. 2002 Feb;6(1):17-23. doi: 10.1023/a:1014168021615. PubMed 11839879 ↗
  • Eckardt L, Doldi F, Anwar O, Gessler N, Scherschel K, Kahle AK, von Falkenhausen AS, Thaler R, Wolfes J, Metzner A, Meyer C, Willems S, Kobe J, Lange PS, Frommeyer G, Kuck KH, Kaab S, Steinbeck G, Sinner MF. Major in-hospital complications after catheter ablation of cardiac arrhythmias: individual case analysis of 43 031 procedures. Europace. 2023 Dec 28;26(1):euad361. doi: 10.1093/europace/euad361. PubMed 38102318 ↗
  • Sharma PS, Patel NR, Ravi V, Zalavadia DV, Dommaraju S, Garg V, Larsen TR, Naperkowski AM, Wasserlauf J, Krishnan K, Young W, Pokharel P, Oren JW, Storm RH, Trohman RG, Huang HD, Subzposh FA, Vijayaraman P. Clinical outcomes of left bundle branch area pacing compared to right ventricular pacing: Results from the Geisinger-Rush Conduction System Pacing Registry. Heart Rhythm. 2022 Jan;19(1):3-11. doi: 10.1016/j.hrthm.2021.08.033. Epub 2021 Sep 3. PubMed 34481985 ↗
  • Vijayaraman P, Ponnusamy S, Cano O, Sharma PS, Naperkowski A, Subsposh FA, Moskal P, Bednarek A, Dal Forno AR, Young W, Nanda S, Beer D, Herweg B, Jastrzebski M. Left Bundle Branch Area Pacing for Cardiac Resynchronization Therapy: Results From the International LBBAP Collaborative Study Group. JACC Clin Electrophysiol. 2021 Feb;7(2):135-147. doi: 10.1016/j.jacep.2020.08.015. Epub 2020 Oct 28. PubMed 33602393 ↗
  • Ponnusamy SS, Vijayaraman P. Late dislodgement of left bundle branch pacing lead and successful extraction. J Cardiovasc Electrophysiol. 2021 Aug;32(8):2346-2349. doi: 10.1111/jce.15155. Epub 2021 Jul 16. PubMed 34245478 ↗
  • De Pooter J, Calle S, Timmermans F, Van Heuverswyn F. Left bundle branch area pacing using stylet-driven pacing leads with a new delivery sheath: A comparison with lumen-less leads. J Cardiovasc Electrophysiol. 2021 Feb;32(2):439-448. doi: 10.1111/jce.14851. Epub 2021 Jan 4. PubMed 33355969 ↗
  • Chen X, Wei L, Bai J, Wang W, Qin S, Wang J, Liang Y, Su Y, Ge J. Procedure-Related Complications of Left Bundle Branch Pacing: A Single-Center Experience. Front Cardiovasc Med. 2021 Mar 24;8:645947. doi: 10.3389/fcvm.2021.645947. eCollection 2021. PubMed 33869306 ↗
  • Ravi V, Larsen T, Ooms S, Trohman R, Sharma PS. Late-onset interventricular septal perforation from left bundle branch pacing. HeartRhythm Case Rep. 2020 Jun 17;6(9):627-631. doi: 10.1016/j.hrcr.2020.06.008. eCollection 2020 Sep. No abstract available. PubMed 32983881 ↗
  • Ponnusamy SS, Vijayaraman P. Aborted ST-elevation myocardial infarction-An unusual complication of left bundle branch pacing. HeartRhythm Case Rep. 2020 May 26;6(8):520-522. doi: 10.1016/j.hrcr.2020.05.010. eCollection 2020 Aug. No abstract available. PubMed 32817832 ↗
  • Vijayaraman P, Subzposh FA, Naperkowski A, Panikkath R, John K, Mascarenhas V, Bauch TD, Huang W. Prospective evaluation of feasibility and electrophysiologic and echocardiographic characteristics of left bundle branch area pacing. Heart Rhythm. 2019 Dec;16(12):1774-1782. doi: 10.1016/j.hrthm.2019.05.011. Epub 2019 May 25. PubMed 31136869 ↗
  • Palmisano P, Ziacchi M, Dell'Era G, Donateo P, Ammendola E, Coluccia G, Guido A, Piemontese GP, Lazzeri M, Ghiglieno C, Veroli A, Maggi R, Russo V, Rago A, Nigro G, Senes J, Patti G, Biffi M, Accogli M. Rate and nature of complications of conduction system pacing compared with right ventricular pacing: Results of a propensity score-matched analysis from a multicenter registry. Heart Rhythm. 2023 Jul;20(7):984-991. doi: 10.1016/j.hrthm.2023.03.009. Epub 2023 Mar 10. PubMed 36906165 ↗
  • Vijayaraman P, West M, Dresing T, Oren J, Abbey S, Zimmerman P, Bauer R, Butler K, Mangrolia H. Safety and performance of conduction system pacing: Real-world experience from a product surveillance registry. Heart Rhythm. 2025 Feb;22(2):318-324. doi: 10.1016/j.hrthm.2024.06.061. Epub 2024 Jul 3. PubMed 38969050 ↗
  • Rushton L. Further follow up of mortality in a United Kingdom oil distribution centre cohort. Br J Ind Med. 1993 Jun;50(6):561-9. doi: 10.1136/oem.50.6.561. PubMed 8329322 ↗
  • Zhan C, Baine WB, Sedrakyan A, Steiner C. Cardiac device implantation in the United States from 1997 through 2004: a population-based analysis. J Gen Intern Med. 2008 Jan;23 Suppl 1(Suppl 1):13-9. doi: 10.1007/s11606-007-0392-0. PubMed 18095038 ↗
  • Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010 Dec 16;363(25):2385-95. doi: 10.1056/NEJMoa1009540. Epub 2010 Nov 14. PubMed 21073365 ↗
  • Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 Oct 1;361(14):1329-38. doi: 10.1056/NEJMoa0906431. Epub 2009 Sep 1. PubMed 19723701 ↗
  • Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 2;52(23):1834-1843. doi: 10.1016/j.jacc.2008.08.027. Epub 2008 Nov 7. PubMed 19038680 ↗
  • Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49. doi: 10.1056/NEJMoa050496. Epub 2005 Mar 7. PubMed 15753115 ↗
  • Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002 Jun 13;346(24):1845-53. doi: 10.1056/NEJMoa013168. PubMed 12063368 ↗
  • Pothineni NVK, Gondi S, Cherian T, Kovelamudi S, Schaller RD, Lakkireddy D, Gopinathannair R, Deshmukh A. Complications of Cardiac Resynchronization Therapy: Comparison of Safety Outcomes from Real-world Studies and Clinical Trials. J Innov Card Rhythm Manag. 2022 Aug 15;13(8):5121-5125. doi: 10.19102/icrm.2022.130805. eCollection 2022 Aug. PubMed 36072440 ↗
  • Kobe J, Andresen D, Maier S, Stellbrink C, Kleemann T, Gonska BD, Reif S, Hochadel M, Senges J, Eckardt L. Complications and 1-year benefit of cardiac resynchronization therapy in patients over 75 years of age - Insights from the German Device Registry. Int J Cardiol. 2017 Feb 1;228:784-789. doi: 10.1016/j.ijcard.2016.11.212. Epub 2016 Nov 10. PubMed 27898337 ↗
  • Providencia R, Marijon E, Lambiase PD, Bouzeman A, Defaye P, Klug D, Amet D, Perier MC, Gras D, Algalarrondo V, Deharo JC, Leclercq C, Fauchier L, Babuty D, Bordachar P, Sadoul N, Piot O, Boveda S. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry. J Am Heart Assoc. 2016 Feb 12;5(2):e002756. doi: 10.1161/JAHA.115.002756. PubMed 26873687 ↗
  • Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014 May;35(18):1186-94. doi: 10.1093/eurheartj/eht511. Epub 2013 Dec 17. PubMed 24347317 ↗
  • Padeletti L, Musilli N, Porciani MC, Colella A, Di Biase L, Ricciardi G, Pieragnoli P, Michelucci A, Gensini G. Atrial fibrillation and cardiac resynchronization therapy: the MASCOT study. Europace. 2004 Sep;5 Suppl 1:S49-54. doi: 10.1016/j.eupc.2004.07.007. PubMed 15450280 ↗
  • Banks H, Torbica A, Valzania C, Varabyova Y, Prevolnik Rupel V, Taylor RS, Hunger T, Walker S, Boriani G, Fattore G; MedtecHTA group. Five year trends (2008-2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases. Europace. 2018 Apr 1;20(4):643-653. doi: 10.1093/europace/eux123. PubMed 29016747 ↗
  • Ezzat VA, Lee V, Ahsan S, Chow AW, Segal O, Rowland E, Lowe MD, Lambiase PD. A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation? Open Heart. 2015 Feb 17;2(1):e000198. doi: 10.1136/openhrt-2014-000198. eCollection 2015. PubMed 25745566 ↗
  • Jastrzebski M, Kielbasa G, Cano O, Curila K, Heckman L, De Pooter J, Chovanec M, Rademakers L, Huybrechts W, Grieco D, Whinnett ZI, Timmer SAJ, Elvan A, Stros P, Moskal P, Burri H, Zanon F, Vernooy K. Left bundle branch area pacing outcomes: the multicentre European MELOS study. Eur Heart J. 2022 Oct 21;43(40):4161-4173. doi: 10.1093/eurheartj/ehac445. PubMed 35979843 ↗
  • Su L, Wang S, Wu S, Xu L, Huang Z, Chen X, Zheng R, Jiang L, Ellenbogen KA, Whinnett ZI, Huang W. Long-Term Safety and Feasibility of Left Bundle Branch Pacing in a Large Single-Center Study. Circ Arrhythm Electrophysiol. 2021 Feb;14(2):e009261. doi: 10.1161/CIRCEP.120.009261. Epub 2021 Jan 9. PubMed 33426907 ↗
  • Koniari I, Gerakaris A, Kounis N, Velissaris D, Rao A, Ainslie M, Adlan A, Plotas P, Ikonomidis I, Mplani V, Hung MY, de Gregorio C, Kolettis T, Gupta D. Outcomes of Atrioventricular Node Ablation and Pacing in Patients with Heart Failure and Atrial Fibrillation: From Cardiac Resynchronization Therapy to His Bundle Pacing. J Cardiovasc Dev Dis. 2023 Jun 26;10(7):272. doi: 10.3390/jcdd10070272. PubMed 37504528 ↗
  • Vijayaraman P, Pokharel P, Subzposh FA, Oren JW, Storm RH, Batul SA, Beer DA, Hughes G, Leri G, Manganiello M, Jastremsky JL, Mroczka K, Johns AM, Mascarenhas V. His-Purkinje Conduction System Pacing Optimized Trial of Cardiac Resynchronization Therapy vs Biventricular Pacing: HOT-CRT Clinical Trial. JACC Clin Electrophysiol. 2023 Dec;9(12):2628-2638. doi: 10.1016/j.jacep.2023.08.003. Epub 2023 Sep 13. PubMed 37715742 ↗
  • Herweg B, Mumtaz M, Vijayaraman P. Conduction System Pacing for CRT: A Physiological Alternative. Arrhythm Electrophysiol Rev. 2025 Feb 18;14:e04. doi: 10.15420/aer.2024.10. eCollection 2025. PubMed 40017670 ↗
  • Vlachos K, Letsas KP, Korantzopoulos P, Liu T, Efremidis M, Sideris A. A review on atrioventricular junction ablation and pacing for heart rate control of atrial fibrillation. J Geriatr Cardiol. 2015 Sep;12(5):547-54. doi: 10.11909/j.issn.1671-5411.2015.05.005. PubMed 26512247 ↗
  • Vijayaraman P, Chelu MG, Curila K, Dandamudi G, Herweg B, Mori S, Jastrzebski M, Sharma PS, Shivkumar K, Tung R, Upadhyay G, Vernooy K, Welter-Frost A, Whinnett Z, Zanon F, Ellenbogen KA. Cardiac Conduction System Pacing: A Comprehensive Update. JACC Clin Electrophysiol. 2023 Nov;9(11):2358-2387. doi: 10.1016/j.jacep.2023.06.005. Epub 2023 Aug 16. PubMed 37589646 ↗
  • Vernooy K, Keene D, Huang W, Vijayaraman P. Implant, assessment, and management of conduction system pacing. Eur Heart J Suppl. 2023 Nov 9;25(Suppl G):G15-G26. doi: 10.1093/eurheartjsupp/suad115. eCollection 2023 Nov. PubMed 37970519 ↗
  • Burri H, Jastrzebski M, Cano O, Curila K, de Pooter J, Huang W, Israel C, Joza J, Romero J, Vernooy K, Vijayaraman P, Whinnett Z, Zanon F. EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS). Europace. 2023 Apr 15;25(4):1208-1236. doi: 10.1093/europace/euad043. PubMed 37061848 ↗
  • Hua W, Gu M, Niu H, Gold MR. Advances of Implantation Techniques for Conduction System Pacing. JACC Clin Electrophysiol. 2022 Dec;8(12):1587-1598. doi: 10.1016/j.jacep.2022.09.022. Epub 2022 Nov 30. PubMed 36543514 ↗
  • Burri H, Starck C, Auricchio A, Biffi M, Burri M, D'Avila A, Deharo JC, Glikson M, Israel C, Lau CP, Leclercq C, Love CJ, Nielsen JC, Vernooy K; Reviewers:; Dagres N, Boveda S, Butter C, Marijon E, Braunschweig F, Mairesse GH, Gleva M, Defaye P, Zanon F, Lopez-Cabanillas N, Guerra JM, Vassilikos VP, Martins Oliveira M. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace. 2021 Jul 18;23(7):983-1008. doi: 10.1093/europace/euaa367. PubMed 33878762 ↗
  • Vijayaraman P, Sharma PS, Cano O, Ponnusamy SS, Herweg B, Zanon F, Jastrzebski M, Zou J, Chelu MG, Vernooy K, Whinnett ZI, Nair GM, Molina-Lerma M, Curila K, Zalavadia D, Haseeb A, Dye C, Vipparthy SC, Brunetti R, Moskal P, Ross A, van Stipdonk A, George J, Qadeer YK, Mumtaz M, Kolominsky J, Zahra SA, Golian M, Marcantoni L, Subzposh FA, Ellenbogen KA. Comparison of Left Bundle Branch Area Pacing and Biventricular Pacing in Candidates for Resynchronization Therapy. J Am Coll Cardiol. 2023 Jul 18;82(3):228-241. doi: 10.1016/j.jacc.2023.05.006. Epub 2023 May 21. PubMed 37220862 ↗
  • Yousaf A, Ahmad S, Peltz J, Ahsan MJ, Abbas KS, Muhammad S, Watson C, Asad ZUA, Kim MH. Left bundle branch area pacing vs biventricular pacing for cardiac resynchronization: A systematic review and meta-analysis. Heart Rhythm O2. 2023 Nov 11;4(11):671-680. doi: 10.1016/j.hroo.2023.06.011. eCollection 2023 Nov. PubMed 38034886 ↗
  • Morcos R, Vijayaraman P, Cano O, Zanon F, Ponnusamy SS, Herweg B, Sharma PS, Jastrzebski M, Molina-Lerma M, Whinnett ZI, Vernooy K, Zou J, Nair GM, Pathak RK, Tung R, Upadhyay GA, Curila K, Chelu MG, Ellenbogen KA. Left bundle branch area pacing compared with biventricular pacing for cardiac resynchronization therapy in patients with left ventricular ejection fraction </=50%: Results from the International Collaborative LBBAP Study (I-CLAS). Heart Rhythm. 2025 Aug;22(8):2028-2037. doi: 10.1016/j.hrthm.2025.04.005. Epub 2025 Apr 25. PubMed 40288475 ↗
  • Zheng Z, Jiang L, Gao Y, Peng X, Feng H, Lu J. Left bundle branch area pacing vs. biventricular pacing significantly improves clinical outcomes and cardiac remodeling in cardiac resynchronization therapy: a systematic review and meta-analysis. Front Cardiovasc Med. 2025 Nov 21;12:1644033. doi: 10.3389/fcvm.2025.1644033. eCollection 2025. PubMed 41357080 ↗
  • Kumar N, Kumar A, Akhtar S, Khan AA, Khan RFU, Lohana N, Ladhani D, Memon B, Kumaran SS, Barzallo P, Rana JS, Shah S, Alraies MC. Left Bundle Branch Area Pacing Versus Biventricular Pacing in Cardiac Resynchronization Therapy: A Systematic Review and Meta-Analysis. Crit Pathw Cardiol. 2026 Jun 1;25(2):e0414. doi: 10.1097/HPC.0000000000000414. Epub 2026 Jan 14. PubMed 41533837 ↗
  • Burri H, Leclercq C, Behar N, Deharo JC, Jastrzebski M, Joza J, Nielsen JC. Controversy: in heart failure patients with a reduced ejection fraction and left bundle branch block, conduction system pacing can be a valid alternative to biventricular pacing-pro and contra. Europace. 2025 Dec 1;27(12):euaf312. doi: 10.1093/europace/euaf312. PubMed 41433135 ↗
  • Cleland JG, Calvert MJ, Verboven Y, Freemantle N. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J. 2009 Mar;157(3):457-66. doi: 10.1016/j.ahj.2008.11.006. Epub 2009 Jan 20. PubMed 19249415 ↗
  • Leventopoulos G, Travlos CK, Anagnostopoulou V, Patrinos P, Papageorgiou A, Perperis A, Gale CP, Gatzoulis KAlpha, Davlouros P. Clinical Outcomes of Left Bundle Branch Area Pacing Compared with Biventricular Pacing in Patients with Heart Failure Requiring Cardiac Resynchronization Therapy: Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2023 Nov 9;24(11):312. doi: 10.31083/j.rcm2411312. eCollection 2023 Nov. PubMed 39076431 ↗
  • Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010 Apr 15;362(15):1363-73. doi: 10.1056/NEJMoa1001337. Epub 2010 Mar 15. PubMed 20231232 ↗
  • Orlov MV, Gardin JM, Slawsky M, Bess RL, Cohen G, Bailey W, Plumb V, Flathmann H, de Metz K. Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation. Am Heart J. 2010 Feb;159(2):264-70. doi: 10.1016/j.ahj.2009.11.012. PubMed 20152225 ↗
  • Khan MS, Shahid I, Anker SD, Fonarow GC, Fudim M, Hall ME, Hernandez A, Morris AA, Shafi T, Weir MR, Zannad F, Bakris GL, Butler J. Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 Jan 24;81(3):270-282. doi: 10.1016/j.jacc.2022.10.028. PubMed 36653095 ↗
  • Claudel SE, Verma A. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review. Circulation. 2025 Mar 11;151(10):716-732. doi: 10.1161/CIRCULATIONAHA.124.071079. Epub 2025 Mar 10. PubMed 40063723 ↗
  • Li Y, Jiang R, Ouyang C, Wang J, Yu Q, Lu J, Hong W, Liu S, Chen Y, Cai J, Yuan H, Zhang L, Lu Y. Chronic kidney disease is associated with increased risk of sudden cardiac death. Nat Commun. 2025 Oct 16;16(1):9180. doi: 10.1038/s41467-025-64254-9. PubMed 41102190 ↗
  • Huang YJ, Hsu YL, Chuang YH, Lin HY, Chen YH, Chan TC. Association between renal function and cardiovascular mortality: a retrospective cohort study of elderly from health check-up. BMJ Open. 2021 Sep 21;11(9):e049307. doi: 10.1136/bmjopen-2021-049307. PubMed 34548356 ↗
  • Karimpour P, May JM, Kyriacou PA. Photoplethysmography for the Assessment of Arterial Stiffness. Sensors (Basel). 2023 Dec 17;23(24):9882. doi: 10.3390/s23249882. PubMed 38139728 ↗
  • Diana G, Scardulla F, Puleo S, Pasta S, D'Acquisto L. Non-Invasive Estimation of Arterial Stiffness Using Photoplethysmography Sensors: An In Vitro Approach. Sensors (Basel). 2025 May 24;25(11):3301. doi: 10.3390/s25113301. PubMed 40968857 ↗
  • Chirinos JA. Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc Transl Res. 2012 Jun;5(3):243-55. doi: 10.1007/s12265-012-9359-6. Epub 2012 Mar 24. PubMed 22447229 ↗
  • Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1825-33. doi: 10.1056/NEJMoa021328. PubMed 12466506 ↗
  • Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1834-40. doi: 10.1056/NEJMoa021375. PubMed 12466507 ↗
  • Vajapey R, Chung MK. Emerging Technologies in Cardiac Pacing. Annu Rev Med. 2024 Jan 29;75:475-492. doi: 10.1146/annurev-med-051022-042616. Epub 2023 Nov 21. PubMed 37989145 ↗
  • van Barreveld M, Verstraelen TE, van Dessel PFHM, Boersma LVA, Delnoy PPHM, Tuinenburg AE, Theuns DAMJ, van der Voort PH, Kimman GJ, Buskens E, Zwinderman AH, Wilde AAM, Dijkgraaf MGW; DO-IT Registry Investigators. Dutch Outcome in Implantable Cardioverter-Defibrillator Therapy: Implantable Cardioverter-Defibrillator-Related Complications in a Contemporary Primary Prevention Cohort. J Am Heart Assoc. 2021 Apr 6;10(7):e018063. doi: 10.1161/JAHA.120.018063. Epub 2021 Mar 31. PubMed 33787324 ↗
  • Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available. PubMed 39210723 ↗
  • Joza J, Burri H, Andrade JG, Linz D, Ellenbogen KA, Vernooy K. Atrioventricular node ablation for atrial fibrillation in the era of conduction system pacing. Eur Heart J. 2024 Dec 7;45(46):4887-4901. doi: 10.1093/eurheartj/ehae656. PubMed 39397777 ↗
  • Alam M, Bandeali SJ, Shahzad SA, Lakkis N. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. Expert Rev Cardiovasc Ther. 2012 Mar;10(3):283-91. doi: 10.1586/erc.12.8. PubMed 22390799 ↗
  • Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, Mountantonakis SE, Gibson DN, Harding JD, Ellis CR, Ellenbogen KA, DeLurgio DB, Osorio J, Achyutha AB, Schneider CW, Mugglin AS, Albrecht EM, Stein KM, Lehmann JW, Mansour M; ADVENT Investigators. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023 Nov 2;389(18):1660-1671. doi: 10.1056/NEJMoa2307291. Epub 2023 Aug 27. PubMed 37634148 ↗
  • Fusco A, Hansen ML, Ruwald MH, Zorner CR, Riis-Vestergaard L, Middelfart C, Hein R, Rasmussen PV, Di Sabatino A, Gislason G, Tonnesen J. Temporal Trends in Atrial Fibrillation Ablation in the Elderly: Incidence of MACE and Recurrence Rates. JACC Clin Electrophysiol. 2025 Jan;11(1):83-94. doi: 10.1016/j.jacep.2024.09.024. Epub 2024 Nov 13. PubMed 39545916 ↗
  • Kneeland PP, Fang MC. Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med. 2009 Sep;4(7):E1-5. doi: 10.1002/jhm.445. PubMed 19753578 ↗
  • Sohns C, Moersdorf M, Marrouche NF, Bergau L, Costard-Jaeckle A, Crijns HJGM, Fox H, Hindricks G, Dagres N, Sossalla S, Schramm R, Fink T, Hamriti ME, Sciacca V, Didenko M, Konietschke F, Rudolph V, Gummert J, Tijssen JGP, Sommer P; CASTLE HTx Investigators. Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation: Two-Year Follow-Up of the CASTLE-HTx Trial. Circulation. 2024 Dec 3;150(23):1904-1906. doi: 10.1161/CIRCULATIONAHA.124.071517. Epub 2024 Aug 30. No abstract available. PubMed 39213004 ↗
  • Marrouche NF, Kheirkhahan M, Brachmann J. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018 Aug 2;379(5):492. doi: 10.1056/NEJMc1806519. No abstract available. PubMed 30067924 ↗
  • Aliot E, Brandes A, Eckardt L, Elvan A, Gulizia M, Heidbuchel H, Kautzner J, Mont L, Morgan J, Ng A, Szumowski L, Themistoclakis S, Van Gelder IC, Willems S, Kirchhof P. The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. Eur Heart J. 2015 Feb 1;36(5):255-6. doi: 10.1093/eurheartj/ehu476. No abstract available. PubMed 25646394 ↗
  • Jaramillo AP, Jaramillo L, Briones Andriuoli RR, Revilla JC, Castells J, Ibrahimli S, Villacres JL, Garzon Mora N. The Effectiveness of Ablation Therapy for Atrial Fibrillation: A Systematic Review. Cureus. 2023 Aug 23;15(8):e43992. doi: 10.7759/cureus.43992. eCollection 2023 Aug. PubMed 37641724 ↗
  • Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, Calo L, Mascia G, Mont L, Vernooy K, van Dijk V, Allaart C, Fauchier L, Gasparini M, Parati G, Soranna D, Rienstra M, Van Gelder IC; APAF-CRT Trial Investigators. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J. 2021 Dec 7;42(46):4731-4739. doi: 10.1093/eurheartj/ehab569. PubMed 34453840 ↗
  • Sugumar H, Nanayakkara S, Chieng D, Wong GR, Parameswaran R, Anderson RD, Al-Kaisey A, Nalliah CJ, Azzopardi S, Prabhu S, Voskoboinik A, Lee G, McLellan AJ, Ling LH, Morton JB, Kalman JM, Kistler PM. Arrhythmia recurrence is more common in females undergoing multiple catheter ablation procedures for persistent atrial fibrillation: Time to close the gender gap. Heart Rhythm. 2020 May;17(5 Pt A):692-698. doi: 10.1016/j.hrthm.2019.12.013. Epub 2019 Dec 19. PubMed 31866381 ↗
  • Is atrial fibrillation the "new epidemic" in heart health? Understanding that the condition is a permanent one is an important first step is adjusting life with this common arrhythmia. Heart Advis. 2011 Sep;14(9):5. No abstract available. PubMed 27024249 ↗
  • Clinical and Scientific Affairs Council; AAPA. Atrial fibrillation: more help for the most common arrhythmia. JAAPA. 2007 May;20(5):18, 21. No abstract available. PubMed 17546939 ↗
  • Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J. 2000;27(3):257-67. PubMed 11093410 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jun 2030, 47 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 47 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 22, 2026
StartEst.
Jul 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07604727
Responsible party
M. Rienstra (MD, PhD, MHA, Professor of Clinical Cardiology, University Medical Center Groningen) — Principal investigator
First posted
May 22, 2026
Start date
Jul 2026 (estimated)
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
May 22, 2026

Study contacts

Michiel Rienstra, MD, PhD, MHA, Professor
Contact
m.rienstra@umcg.nl
+31503611327
Ahmed S Yassin, MD
Contact
a.s.e.m.yassin@umcg.nl
Michiel Rienstra, MD, PhD, MHA, Professor
study chair · University Medical Center Groningen, Groningen, The Netherlands
Yuri Blaauw, MD, PhD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion